Teachers Retirement System of The State of Kentucky decreased its position in Kenvue Inc. (NYSE:KVUE – Free Report) by 4.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 140,787 shares of the company’s stock after selling 7,240 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Kenvue were worth $3,021,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds also recently bought and sold shares of the company. Manchester Capital Management LLC increased its holdings in shares of Kenvue by 80.8% in the first quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock worth $25,000 after buying an additional 530 shares during the period. Pacific Capital Wealth Advisors Inc. bought a new stake in Kenvue in the fourth quarter valued at approximately $28,000. Mather Group LLC. purchased a new stake in shares of Kenvue during the first quarter valued at approximately $28,000. Oakworth Capital Inc. purchased a new stake in shares of Kenvue during the first quarter valued at approximately $31,000. Finally, Pinnacle Bancorp Inc. grew its holdings in shares of Kenvue by 51.3% in the fourth quarter. Pinnacle Bancorp Inc. now owns 1,552 shares of the company’s stock worth $33,000 after purchasing an additional 526 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.
Kenvue Stock Performance
Shares of KVUE stock traded up $0.19 on Friday, reaching $18.82. The stock had a trading volume of 17,688,715 shares, compared to its average volume of 16,514,614. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.99. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.43. The stock has a market cap of $36.04 billion, a P/E ratio of 24.13, a price-to-earnings-growth ratio of 2.07 and a beta of 1.38. The company has a 50 day simple moving average of $18.49 and a 200 day simple moving average of $19.44.
Kenvue Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 28th. Investors of record on Wednesday, August 14th will be paid a dividend of $0.205 per share. The ex-dividend date is Wednesday, August 14th. This is an increase from Kenvue’s previous quarterly dividend of $0.20. This represents a $0.82 dividend on an annualized basis and a dividend yield of 4.36%. Kenvue’s payout ratio is 102.56%.
Analyst Upgrades and Downgrades
A number of research analysts have commented on KVUE shares. JPMorgan Chase & Co. lowered their price target on Kenvue from $23.00 to $22.00 and set an “overweight” rating for the company in a research report on Monday, July 22nd. HSBC raised their price target on Kenvue from $20.00 to $21.00 and gave the stock a “hold” rating in a research note on Wednesday, May 8th. Sanford C. Bernstein began coverage on shares of Kenvue in a research report on Thursday, April 11th. They set an “underperform” rating and a $18.00 price objective on the stock. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Kenvue from $24.00 to $23.00 and set a “buy” rating for the company in a research report on Thursday, July 25th. Finally, Citigroup reduced their price target on shares of Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 10th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $22.45.
Check Out Our Latest Report on KVUE
Kenvue Profile
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
See Also
- Five stocks we like better than Kenvue
- What Investors Need to Know to Beat the Market
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.